Medtronic's MiniMed Swap Window Narrows as Wall Street Zen Turns Bullish

Medtronic's MiniMed exchange offer prices Oct 5-7 and closes Oct 9, 2026, as Wall Street Zen upgrades the stock to Buy after strong fiscal 2026 revenue growth.

Medtronic has entered the final stretch of its most significant corporate restructuring in years, with the pricing of its MiniMed diabetes spinoff now locked into an early-October window. According to a Nasdaq notice, the pricing period for the exchange offer runs from October 5 to 7, 2026, with the offer itself set to close on October 9, 2026. Shareholders can swap their Medtronic stock for newly created MiniMed Group shares through the official exchange offer, and management has already cleaned up administrative settlement details with the SEC ahead of the launch.

The stock has been treading water as investors wait for the separation to play out. Medtronic closed Friday's session at EUR 76.72, giving the medical device maker a market capitalization of EUR 98.13 billion. Over the past 30 days, the shares have shed 3.6%, while the diabetes unit earmarked for the spinoff has slipped 2.2% since the split was announced roughly three weeks ago.

A Fresh Upgrade to Close the Week

Sentiment got a lift over the weekend when Wall Street Zen raised its rating on Medtronic from Hold to Buy on Sunday. The upgrade lands after a string of quarterly reports that have kept the company on track, and it comes as defensive healthcare names draw renewed interest from market watchers.

The operating numbers back up the more constructive stance. Medtronic posted its strongest revenue growth in a decade during fiscal 2026, expanding 8.4%, and that momentum carried into the first quarter of fiscal 2027 with a nearly 14% jump in sales. The quarterly report released on September 1 beat expectations, showing revenue of USD 9.76 billion and adjusted earnings per share of USD 1.45. Management is guiding for full-year fiscal 2027 EPS of USD 5.94 to USD 6.00.

New technologies are expected to fuel further gains, with the Hugo surgical robotics platform among the key growth drivers. The broader medical technology sector also offers some shelter, since procedures and treatments are largely insulated from economic cycles — a quality that stands out at a time of persistently elevated interest rates and choppy bond yields.

Pipeline Momentum Across the Franchise

While the corporate structure is being streamlined, Medtronic is pressing ahead with clinical development, particularly in cardiology and vascular medicine. On Wednesday, the company announced a randomized pivotal trial for its IN.PACT BTK drug-coated balloon catheter, targeting roughly 400 patients with blockages below the knee. The FDA had already granted the device breakthrough status.

The trial program is designed to build the evidence base for the catheter technology. Medtronic also strengthened its robotic surgery offering, securing FDA clearance for the LigaSure RAS Maryland surgical instrument, which is built specifically for use with the Hugo robotic system.

Reimbursement groundwork is advancing in parallel. The American Medical Association granted Category I CPT codes for the Altaviva incontinence system and the Symplicity Spyral renal denervation system for high blood pressure. These classifications replace older transitional codes and take effect in January 2028. Medtronic noted that the coding alone does not guarantee payer coverage, though standardized classification meaningfully improves the odds of broader clinical adoption.

Cardiac Unit Restructuring and a Steady Dividend

Beyond the MiniMed separation, Medtronic is reportedly reorganizing its cardiovascular business into two separate units. As part of that effort, the Santa Rosa, California facility — which traces its roots to a 1998 acquisition — is slated to close within two years, with media reports pointing to roughly 370 job cuts there by spring 2027.

For income-focused investors, the payout remains a cornerstone. Medtronic has raised its dividend for 49 consecutive years. The next quarterly distribution of USD 0.72 per share, equivalent to an annualized USD 2.88, is payable on October 16 to shareholders of record as of the September 25 cutoff.

Analyst support extends beyond the weekend upgrade. On Wednesday, Joshua Jennings of TD Cowen reaffirmed his Buy rating and kept his price target at USD 110. How smoothly the MiniMed separation proceeds — and what the newly launched trials ultimately deliver — will shape where the stock heads from here.